The efficacy and safety of tenapanor plus PBs in Chinese patients are still unclear. Therefore, we aim to conduct a real-world study to explore the effect of combining two drugs with different mechanisms on hyperphosphatemia management.This real-world study will enroll hemodialysis patients with hyperphosphatemia who are on PBs therapy.
The subject has provided written informed consent prior to the initiation of any study-related activities.
Male or female subjects aged ≥18 years at the time of signing the informed consent form.
The subject is receiving regular maintenance hemodialysis (3 times per week, 4 hours per session) for at least 3 months.
The patient has been on phosphate binder therapy for at least 3 weeks, with a stable dose.
Hypersensitivity to Tenapanor or any excipients of the formulation.
History of diarrhea within 1 week prior to the start of treatment. Diarrhea is defined as a Bristol Stool Form Scale (BSFS) score ≥6 (i.e., mushy or liquid stools with no solid pieces), a daily bowel movement frequency ≥3 times, and a duration of ≥2 days.
Life expectancy < 6 months.
Expected or planned kidney transplantation during the study period.